الفهرس 
Epithelial ovarian cancerOnly 14 pages are availabe for public view
 |  | from | 7 |  |  |
| | | from | 7 | | |
Abstract
The study may prove that: CTCs allow early detection of ovarian cancer even in
asymptomatic patients
CTCs are well correlated with FIGO stage
CTCs are absent in benign and borderline ovarian tumors.
CTCs can be used to discriminate between early and late FIGO
stage at a cutoff level of > 0.82 cell/ul, with 66.7% sensitivity,
90.9% specificity, 88% PPV and 73.2% NPV (AUC = 0.65 &
p-value = 0.076).
CTCs can be used to discriminate between patients with
optimum debulking and patients without optimum debulking at
a cutoff level of < 1.9 cell/ul, with 100% sensitivity, 60% specificity, 71.4% PPV and 100% NPV (AUC = 0.65 & p-value
= 0.063).